# US 2001/0020019 A1 · Novel halo-alkoxycarbonyl prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0020019 A1
- Document ID: US20010020019A1
- Status: Published application
- Kind: A1
- Application number: 09/059,808
- Filed: 1998-04-14
- Published: 2001-09-06
- Earliest claimed: 1997-04-15
- Assignees: Genentech, Inc.
- Inventors: BRENT BLACKBURN; ALAN G. OLIVERO; KIRK ROBARGE
- Web page: https://patentgrep.com/patent/US20010020019A1

## CPC

- C07D 243/14: 1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Halo-alkoxycarbonyl derivatives are provided as prodrug moieties for pharmaceutical agents containing a basic or polar nitrogen containing functionality. The prodrugs are provided as pharmaceutical compositions as well as in methods of treatment.

## Claims

### Claim 1

A compound of the formula: 15
wherein [(H)0-2(X)1-3] is selected from the group consisting of X3, HX2, and H2X and X is a halogen selected from the group consisting of F, Cl, Br, I or a combination thereof; R2 and R3 are the same or different and are selected from the group consisting of H, C1-C4alkyl, C1-C4alkoxy, cyano, halo(F, Cl, Br, I)C1-C4alkyl and aryl, AG-Q is a biologically active pharmaceutical agent wherein Q is a basic N-containing functionality selected from the group consisting of an amino, amidino, aminoalkyleneamino, iminoalkyleneamino, and guanidino group.

### Claim 2 (depends on 1)

The compound of claim 1 wherein X is Cl and R2 and R3 are the same or different and are selected from the group consisting of H, C1-C4alkyl and aryl.

### Claim 3 (depends on 2)

The compound of claim 2 wherein the C1-C4alkyl is selected from the group consisting of methyl, ethyl, propyl, and butyl.

### Claim 4 (depends on 3)

The compound of claim 3 wherein the C1-C4alkyl is methyl.

### Claim 5 (depends on 4)

The compound of claim 4 wherein R2 and R3 are the same.

### Claim 6 (depends on 5)

The compound of claim 5 wherein R2 and R3 are H.

### Claim 7 (depends on 6)

The compound of claim 6 where [(H)0-2(X)1-3] is X3.

### Claim 8 (depends on 1)

The compound of claim 1 wherein Q is selected from the group consisting of an amidino and a guanidino group.

### Claim 9 (depends on 8)

The compound of claim 8 wherein Q is an amidino group selected from the group consisting of: 16

### Claim 10 (depends on 8)

The compound of claim 8 wherein Q is selected from the group consisting of: 17

### Claim 11 (depends on 9)

The compound of claim 9 wherein the Q is an amidino group B-Q wherein Q is —C(═NH)—NH2 and B is selected from the group consisting of a substituted or unsubstituted alkyl, alkenyl or alkynyl, a substituted or unsubstituted aryl, arylalkyl, heterocyclic, and heteroaromatic.

### Claim 12 (depends on 11)

The compound of claim 11 wherein B is selected from the group consisting of a substituted or unsubstituted alkyl, aryl or arylalkyl.

### Claim 13 (depends on 12)

The compound of claim 12 wherein B is a substituted or unsubstituted aryl.

### Claim 14 (depends on 13)

The compound of claim 13 wherein B is an aryl.

### Claim 15 (depends on 14)

The compound of claim 14 wherein B is selected from the group consisting of phenyl, napthyl, or pyridyl.

### Claim 16 (depends on 15)

The compound of claim 15 wherein B is an unsubstituted phenyl.

### Claim 17 (depends on 16)

The compound of claim 16 wherein AG-Q is: 18
wherein -A-B- is selected from the group consisting of: 19

### Claim 18 (depends on 1)

The compound of claim 1 wherein AG-Q is a thrombin inhibitor, a platelet aggregation inhibitor, a GPIIb/IIIa receptor blocker, or a Factor Xa inhibitor.

### Claim 19

A compound having one of the following two tautomeric structures: 20
wherein AG represents a biologically active parent pharmaceutical agent substructure and wherein P and P′ are the same or different and are independently selected from H or a trichloroethoxycarbonyl moiety, at least one of P or P′ being a trichloroethoxycarbonyl moiety and B is selected from the group consisting of a substituted or unsubstituted alkyl, alkenyl or alkynyl, a substituted or unsubstituted aryl, arylalkyl, heterocyclic, and heteroaromatic.

### Claim 20 (depends on 19)

The compound of claim 19 wherein B is selected from the group consisting of a substituted or unsubstituted alkyl, aryl or arylalkyl.

### Claim 21 (depends on 20)

The compound of claim 20 wherein B is a substituted or unsubstituted aryl.

### Claim 22 (depends on 21)

The compound of claim 21 wherein B is an aryl.

### Claim 23 (depends on 22)

The compound of claim 22 wherein B is selected from the group consisting of phenyl, napthyl, or pyridyl.

### Claim 24 (depends on 23)

The compound of claim 23 wherein B is an unsubstituted phenyl.

### Claim 25 (depends on 1)

A pharmaceutical composition in unit dosage form adapted for oral administration comprising a prodrug of claim 1 and a pharmaceutically acceptable carrier therefor.

### Claim 26 (depends on 25)

A method of treatment comprising orally administering to a human or non-human animal in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 25.
